Is Fat in the Liver a Marker of Post-Pregnancy Glycaemic Deterioration in Women With Gestational Diabetes?

RecruitingOBSERVATIONAL
Enrollment

95

Participants

Timeline

Start Date

May 5, 2019

Primary Completion Date

June 30, 2025

Study Completion Date

December 30, 2025

Conditions
Gestational Diabetes
Interventions
DIAGNOSTIC_TEST

MRI scan

On attendance to antenatal clinic with confirmed diagnosis of gestational diabetes based on OGTT and following informed consent: Ultrasound scan: Those with positive OGTT results (i.e. GDM positive) will attend an appointment for an ultrasound scan, as per routine practice. These women will,at that appointment, be assessed for presence/absence of NAFLD as well as undergoing their routine foetal assessment. This is a simple addendum to the existing scan, taking no more than 5 minutes. Participants will have been informed during the consent process that the results (regarding the presence / absence of NAFLD) will be compared to MRI after delivery.

Trial Locations (1)

ST4 6QG

RECRUITING

University Hospitals of North Midlands NHS Trust, Stoke-on-Trent

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Diabetes UK

OTHER

lead

University Hospitals of North Midlands NHS Trust

OTHER

NCT04362540 - Is Fat in the Liver a Marker of Post-Pregnancy Glycaemic Deterioration in Women With Gestational Diabetes? | Biotech Hunter | Biotech Hunter